M&A Deal Summary

Collegium Pharmaceutical Acquires BioDelivery

On February 14, 2022, Collegium Pharmaceutical acquired life science company BioDelivery for 604M USD

Acquisition Highlights
  • This is Collegium Pharmaceutical’s 2nd transaction in the Life Science sector.
  • This is Collegium Pharmaceutical’s largest (disclosed) transaction.
  • This is Collegium Pharmaceutical’s 2nd transaction in the United States.
  • This is Collegium Pharmaceutical’s 1st transaction in North Carolina.

M&A Deal Summary
Date 2022-02-14
Target BioDelivery
Sector Life Science
Buyer(s) Collegium Pharmaceutical
Deal Type Add-on Acquisition
Deal Value 604M USD
Advisor(s) Moelis & Co. (Financial)
Goodwin Procter (Legal)

Target

BioDelivery

Raleigh, North Carolina, United States
website
BioDelivery is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of differentiated pain and neurology products and leverages its experienced sales and marketing organization to educate prescribers on their unique features. BioDelivery was formed in 1997 and is based in Raleigh, North Carolina.

Search 193,605 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Collegium Pharmaceutical

Stoughton, Massachusetts, United States

website

Category Company
Founded 2002
Sector Life Science
Employees152
Revenue 277M USD (2021)
DESCRIPTION

Collegium Pharmaceutical offers specialty pharmaceutical services by developing and planning to commercialize next-generation, abuse-deterrent products for patients suffering from chronic pain. Collegium Pharmaceutical was founded in 2002 and is based in Stoughton, Massachusetts.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 1 of 1
State (North Carolina) 1 of 1
Country (United States) 2 of 2
Year (2022) 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-02-06 Assertio Therapeutics - NUCYNTA

California, United States

Assertio Therapeutics, Inc. - NUCYNTA is a strong prescription pain medicine that contains an opioid (narcotic) that is used to manage short-term (acute) pain in adults when other pain treatments, such as non-opioid pain medicines, do not treat your pain well enough or you cannot tolerate them.

Buy $375M
Mergr

Product

Company

Legal